George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
August 31, 2024 03:54 ET
|
George Medicines
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
August 28, 2024 01:15 ET
|
Novartis Pharma AG
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of...
North America Clinical Trial Supply & Logistics Market Analysis, Competition, Forecasts & Opportunities, 2019-2023 & 2024-2029
August 27, 2024 11:22 ET
|
Research and Markets
Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "North America Clinical Trial Supply & Logistics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to...
MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights Analysis 2024: Focus on 10 ML1 Inhibitor Drug In Clinical Trials, Insight By Company, Indication and Phase
August 26, 2024 11:02 ET
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2024" report has been added to ResearchAndMarkets.com's offering. ...
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
Friedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report
August 20, 2024 06:30 ET
|
FACT.MR
Rockville, MD , Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Global Friedreich’s Ataxia Drug Market is projected at a value of US$ 1 billion in 2024, as revealed in a newly published industry analysis by...
TROP2 Antibody Market & Clinical Trials Report to 2029: Global & Regional Market Insight and Coverage of 45 Drugs In Clinical Trials
August 15, 2024 10:14 ET
|
Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "TROP2 Antibody Market & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. TROP2 (trophoblast cell...
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
August 14, 2024 16:10 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Federal report illuminates need for disability inclusion in clinical trials
August 14, 2024 12:18 ET
|
National Council on Disability
WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Today, the National Council on Disability (NCD) released a timely report on exclusionary practices that prevent people with disabilities from...
In a First for Pharma, Citeline SmartSolutions Take AI to New Levels, Optimizing Clinical Trial Planning and Site Selection
August 13, 2024 09:00 ET
|
Citeline
Citeline has Protocol SmartDesign and Investigator SmartSelect, part of its AI-enabled SmartSolutions suite accelerating the path from pipeline to patient.